Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients - PubMed (original) (raw)

Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients

M Bajaj et al. Int J Obes Relat Metab Disord. 2004 Jun.

Abstract

Objectives: To study the effect of pioglitazone (PIO) on plasma resistin concentration, endogenous glucose production (EGP), and hepatic fat content (HFC) in patients with type II diabetes (T2DM).

Subjects: A total of 13 T2DM patients (age=51+/-2 y, BMI=29.7+/-1.1 kg/m(2), HbA(1c)=8.0+/-0.5%).

Methods: HFC (magnetic resonance spectroscopy) and basal plasma resistin concentration were quantitated before and after PIO treatment (45 mg/day) for 16 weeks. Subjects received a 3 h euglycemic insulin (100 mU/m(2)/min) clamp with 3-[(3)H] glucose to determine rates of EGP and tissue glucose disappearance (Rd) before and after PIO.

Results: PIO reduced fasting plasma glucose (10.3+/-0.7 to 7.6+/-0.6 mmol/l, P<0.001) and HbA(1c) (8.0+/-0.4 to 6.8+/-0.3%, P<0.001) despite increased body weight (83.2+/-3.4 to 86.3+/-3.4 kg, P<0.001). PIO improved Rd (4.9+/-0.4 to 6.6+/-0.5 mg/kg/min, P<0.005) and reduced EGP (0.22+/-0.04 to 0.06+/-0.02 mg/kg/min, P<0.01) during the insulin clamp. Following PIO, HFC decreased from 21.1+/-3.5 to 11.2+/-2.1% (P<0.005), and plasma resistin decreased from 5.3+/-0.6 to 3.5+/-0.3 ng/ml (P<0.01). Plasma resistin concentration correlated positively with HFC before (r=0.58, P<0.05) and after (r=0.55, P<0.05) PIO treatment. Taken collectively, plasma resistin concentration, before and after PIO treatment, correlated positively with hepatic fat content (r=0.66, P<0.001) and EGP during the insulin clamp (r=0.41, P<0.05). However, the plasma resistin concentration did not correlate with whole body glucose disposal (Rd) during the insulin clamp either before (r=-0.18, P=NS) or after (r=-0.13, P=NS) PIO treatment.

Conclusions: PIO treatment in T2DM causes a significant decrease in plasma resistin concentration. The decrease in plasma resistin is positively correlated with the decrease in hepatic fat content and improvement in hepatic insulin sensitivity.

PubMed Disclaimer

Cited by

Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease.
Wang X, Zhao B, Sun H, You H, Qu S. Wang X, et al. Front Endocrinol (Lausanne). 2022 Aug 22;13:866189. doi: 10.3389/fendo.2022.866189. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36072931 Free PMC article. Clinical Trial.
Resistin levels decrease as insulin resistance increases in a Mexican-American cohort.
Gutierrez AD, Flores CA, Naik S, Lee M, Asgarisabet P, Resman M, Lee M, McCormick JB, Fisher-Hoch SP. Gutierrez AD, et al. Cytokine. 2021 Dec;148:155687. doi: 10.1016/j.cyto.2021.155687. Epub 2021 Sep 9. Cytokine. 2021. PMID: 34509726 Free PMC article.
A role for calcium in resistin transcriptional activation in diabetic hearts.
Singh R, Moreno P, Hajjar RJ, Lebeche D. Singh R, et al. Sci Rep. 2018 Oct 23;8(1):15633. doi: 10.1038/s41598-018-34112-4. Sci Rep. 2018. PMID: 30353146 Free PMC article.
Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin.
Al-Muzafar HM, Amin KA. Al-Muzafar HM, et al. Exp Ther Med. 2018 Oct;16(4):2938-2948. doi: 10.3892/etm.2018.6563. Epub 2018 Aug 2. Exp Ther Med. 2018. PMID: 30214514 Free PMC article.
Impact of pioglitazone on bone mineral density and bone marrow fat content.
Pop LM, Lingvay I, Yuan Q, Li X, Adams-Huet B, Maalouf NM. Pop LM, et al. Osteoporos Int. 2017 Nov;28(11):3261-3269. doi: 10.1007/s00198-017-4164-3. Epub 2017 Jul 22. Osteoporos Int. 2017. PMID: 28735463 Clinical Trial.

Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients - PubMed (original) (raw)